Cepheid (CPHD) Earning Somewhat Positive Press Coverage, Analysis Shows
Headlines about Cepheid (NASDAQ:CPHD) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cepheid earned a news impact score of 0.24 on Accern’s scale. Accern also gave media coverage about the scientific and technical instruments company an impact score of 49.0572131560403 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Cepheid (CPHD) remained flat at $52.95 during trading on Friday. Cepheid has a 12 month low of $25.09 and a 12 month high of $53.91. The stock has a 50 day moving average price of $52.75 and a 200 day moving average price of $38.36.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.